CENTESSA PHARMACEUTICALS PLC
Centessa Pharmaceuticals plc is a public biotechnology company focused on the research and experimental development of novel medicines.
Get an alert when CENTESSA PHARMACEUTICALS PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£46M
USD 61,299,000
-84% lowest in 3 filed years
Net assets
£394M
USD 525,729,000
+31.1% highest in 3 filed years
Employees
96
+23.1% highest in 3 filed years
Profit before tax
-£167M
USD -223,582,000
+13.5% vs 2024
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £5,130,259 | £0 | £11,229,226 | — | |
| Operating profit | -£128,225,034 | -£171,187,303 | -£171,818,386 | -0.4% | |
| Profit before tax | -£131,861,806 | -£193,393,472 | -£167,376,853 | +13.5% | |
| Net profit | -£113,104,507 | -£172,553,526 | -£151,183,560 | +12.4% | |
| Cash | £95,845,186 | £286,885,013 | £45,889,355 | -84% | |
| Total assets less current liabilities | £240,201,377 | £410,643,060 | £481,678,395 | +17.3% | |
| Net assets | £176,855,817 | £300,193,891 | £393,568,648 | +31.1% | |
| Equity | £176,855,817 | £300,193,891 | £393,568,648 | +31.1% | |
| Average employees | 79 | 78 | 96 | +23.1% | |
| Wages | £20,443,180 | £21,637,970 | £27,885,911 | +28.9% | |
| Directors' remuneration | — | £1,740,734 | £1,994,666 | +14.6% |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | -53.4% | -41.7% | -35.7% | |
| Gearing (liabilities / total assets) | 34.4% | 30.5% | — | |
| Current ratio | 8.00x | 20.32x | 15.61x | |
| Interest cover | -17.29x | -20.44x | -20.25x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- CENTESSA PHARMACEUTICALS PLC 2021-05-14 → present
- CENTESSA PHARMACEUTICALS LIMITED 2021-02-17 → 2021-05-14
- UNITED MEDICINES BIOPHARMA LIMITED 2020-10-26 → 2021-02-17
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors are satisfied that the going concern basis remains appropriate for the preparation of the Group and the Company financial statements, which assumes that the Group will continue in operation and will be able to realise their assets and discharge their liabilities in the ordinary course of business for at least twelve months from the date of approval of the financial statements.”
Group structure
- CENTESSA PHARMACEUTICALS PLC · parent
- Centessa Pharmaceuticals Holdings Inc. 100%
- Centessa Pharmaceuticals (UK) Limited 100%
- ApcinteX Limited 100%
- Centessa Pharmaceuticals LLC 100%
- Centessa Biosciences Inc formerly known as Palladio Bioscienes Inc 100%
Significant events
- “On 31 March 2026, we entered into a Transaction Agreement (the "Transaction Agreement") with Eli Lilly and Company.”
- “On December 11 2025, the Company announced that Saurabh Saha, M.D., Ph.D., stepped down from his position as CEO and member of the board of directors and that the Company's President and founder of Centessa's Orexin Program, Mario Alberto Accardi, Ph.D, as CEO, both effective 1 January 2026.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
9 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HUSSAIN, Iqbal | Secretary | 2021-04-30 | — | — |
| ACCARDI, Mario Alberto, Dr | Director | 2026-01-01 | Feb 1986 | Italian,British |
| DE RUBERTIS, Francesco | Director | 2020-11-20 | Jan 1970 | Italian |
| GOYAL, Arjun, Dr | Director | 2021-01-29 | Jul 1981 | Australian |
| HEDLEY, Mary Lynne | Director | 2021-02-22 | Aug 1962 | American |
| HUKKELHOVEN, Mathias | Director | 2022-07-01 | Nov 1953 | Dutch |
| KULKARNI, Samarth | Director | 2021-02-22 | Nov 1978 | American |
| STUCKLEY, Carol | Director | 2021-05-17 | Sep 1955 | American |
| ZBAR, Brett, Dr | Director | 2021-01-29 | Aug 1972 | American |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| TAIT, Nicholas Alexander James | Secretary | 2020-10-26 | 2021-04-20 |
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2021-04-30 | 2021-06-02 |
| CALIFF, Robert Mckinnon | Director | 2021-02-22 | 2022-02-16 |
| KANTOFF, Aaron | Director | 2021-01-29 | 2022-07-01 |
| LEE, Richard Michael | Director | 2020-10-26 | 2021-01-29 |
| SAHA, Saurabh, Dr | Director | 2021-01-29 | 2026-01-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mr Richard Michael Lee | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-10-26 | Ceased 2021-01-29 |
Filing timeline
Last 20 of 263 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-06-29 RESOLUTIONS Resolution
- 2026-06-29 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-29 | RESOLUTIONS | resolution | Resolution | |
| 2026-06-29 | MA | incorporation | Memorandum articles | |
| 2026-06-29 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2026-06-29 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2026-06-28 | AA | accounts | Accounts with accounts type group | |
| 2026-06-26 | OC | miscellaneous | Court order | |
| 2026-06-17 | SH01 | capital | Capital allotment shares | |
| 2026-06-17 | SH01 | capital | Capital allotment shares | |
| 2026-03-26 | SH01 | capital | Capital allotment shares | |
| 2026-03-13 | SH01 | capital | Capital allotment shares | |
| 2026-03-09 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-03-06 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-02-13 | CH01 | officers | Change person director company with change date | |
| 2026-02-10 | SH01 | capital | Capital allotment shares | |
| 2026-02-06 | SH01 | capital | Capital allotment shares | |
| 2026-01-29 | SH01 | capital | Capital allotment shares | |
| 2026-01-14 | SH01 | capital | Capital allotment shares | |
| 2026-01-13 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-13 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-18 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 20
- Capital events
- 9
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.